PRCTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
PROCEPT BioRobotics Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$18.28+0.71 (+4.04%)
Close on Oct 19, 2026
- Market cap
- $1.04B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$14.69 (−44.56%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
PROCEPT BioRobotics Corp grew revenue 22.7% to $337.34M over the twelve months to Jun 30, 2026. Free cash flow was -$84.93M.
Revenue
$337.34M
+22.7% vs. a year earlier
Operating income
-$114.23M
TTM Q2 2026
Free cash flow
-$84.93M
TTM Q2 2026
EPS, diluted
-$1.94
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.04B
- P/E ratio
- –
- Price to sales
- 3.09
- Price to book
- 3.07
- Dividend yield
- –
- Free cash flow yield
- -8.14%
Fundamentals
- Revenue
- $337.34M
- Net income
- -$109.76M
- EPS, diluted
- -$1.94
- Free cash flow
- -$84.93M
- Book value per share
- $5.96
- Diluted shares
- 57M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
$337.34M+22.7% YoY
Gross profit
$216.65M+22.8% YoY
Operating income
-$114.23M
Net income
-$109.76M
EPS, diluted
-$1.94
Free cash flow
-$84.93M
Reported periodTrailing twelve months